Risk Factors for Cutaneous Immune-Related Adverse Events: A Systematic Scoping Review

Zhenzhen Su's systematic scoping review summarizes risk factors for cutaneous immune-related adverse events (cirAEs) in cancer patients treated with immune checkpoint inhibitors. The review, published on figshare in 2026, analyzed 50 studies encompassing 198,514 participants, identifying 68 distinct risk factors across demographic, clinical, and biomarker domains. The work aims to address clinical needs for cirAE identification and highlights gaps in high-quality prospective evidence.

Use Cases

• Identify demographic risk factors for cutaneous adverse events based on age, gender, and BMI data.
• Analyze associations between specific treatment regimens (e.g., camrelizumab) and adverse event subtypes.
• Investigate biomarker correlations (e.g., eosinophil count, cytokine levels) with adverse event development.
• Validate reported odds ratios (OR) for risk factors across different tumor types like melanoma.

Strengths

• Systematic methodology following PRISMA-ScR guidelines across 10 databases.
• Large participant pool of 198,514 individuals from 50 included studies.
• Identified 68 distinct risk factors categorized into three primary domains.

Limitations

• Data is a review document (85.3 KB DOCX), not a structured dataset; column-level documentation is absent.
• Row count is unknown, which may limit suitability assessment for direct analysis.
• The review notes significant variability in the quality of reporting for risk factors in the source literature.

Provenance

Source

figshare, author Zhenzhen Su.

Collection Method

Systematic scoping review conducted in accordance with PRISMA-ScR guidelines.

Time Range

Studies from database inception to December 31, 2023.

Freshness

Last updated 2026-04-16 05:18:56.

Geography

Studies published in English and Chinese; geographic coverage of participants is not specified.